Medical Cannabis for Cancer: Pain, Nausea and Palliative Care UK

Cancer and its treatments present some of the most debilitating symptom burdens patients face. Chemotherapy-induced nausea, chronic pain, appetite loss, and severe insomnia can significantly diminish quality of life during an already difficult time. Medical cannabis — legally prescribed in the UK since 2018 — has emerged as a meaningful option for many cancer patients seeking relief from these treatment-related symptoms.

How Medical Cannabis Helps Cancer-Related Symptoms

The endocannabinoid system plays a role in regulating nausea, pain perception, appetite, and sleep — the four primary concerns for cancer patients. Both THC (tetrahydrocannabinol) and CBD (cannabidiol) interact with CB1 and CB2 receptors throughout the body, offering several avenues for symptom relief.

• Chemotherapy-induced nausea and vomiting (CINV): THC has well-documented antiemetic properties. Dronabinol and nabilone — synthetic cannabinoids — are licensed for CINV in several countries. While UK prescribers tend to use whole-plant extracts, the underlying mechanism is the same. Many patients report significantly reduced nausea with a balanced THC:CBD product.
• Chronic and neuropathic pain: Both THC and CBD modulate pain pathways. CBD reduces inflammation via CB2 receptors, while THC alters pain perception centrally. For cancer patients dealing with tumour-related pain or post-surgical neuropathy, a combination product often provides meaningful relief without the tolerance issues associated with opioids.
• Appetite stimulation: THC is well known for stimulating appetite through ghrelin release and hypothalamic signalling. For cancer patients experiencing cachexia (severe weight loss) or treatment-related anorexia, this effect can be clinically significant.
• Sleep disruption: Indica-dominant strains high in myrcene and linalool terpenes promote sedation and deeper sleep cycles. CBD-dominant oils taken at night can also reduce sleep-onset latency without the hangover effect of many pharmaceutical sleep aids.

NICE Guidance and UK Clinical Framework

The National Institute for Health and Care Excellence (NICE) published guidance in 2019 (TA632) on cannabis-based medicinal products. For cancer-related pain and CINV, NICE notes insufficient evidence to recommend specific cannabis products on the NHS — meaning most prescriptions come via private specialist clinics through the Schedule 2 licence route.

Prescriptions must be written by a specialist physician (typically an oncologist, pain specialist, or palliative care consultant) who is on the General Medical Council (GMC) register. Patients cannot receive medical cannabis from a GP for cancer-related symptoms without specialist referral.

The Medicines and Healthcare products Regulatory Agency (MHRA) oversees all licensed cannabis medicinal products in the UK. Unlicensed imports require a Specials licence, which many specialist clinics hold.

UK Clinics Treating Cancer Patients

Several UK specialist clinics have experience treating cancer patients with medical cannabis:

• Curaleaf Clinic — one of the UK's largest providers, with oncology-focused consultants who can prescribe THC-dominant flower and balanced oils for CINV and pain.
• Lyphe Group — offers online specialist consultations; experienced in palliative and oncology referrals.
• Mamedica — monthly subscription model with same-week appointments, suitable for ongoing cancer symptom management.
• Releaf — focuses on rapid access with next-day consultations, useful for acute symptom flares.

To find and compare clinics by services and cost, visit the LeafMe clinic directory.

Recommended THC:CBD Ratios for Cancer Symptoms

There is no single "cancer prescription" — clinicians tailor the product to the patient's dominant symptoms:

• High THC (e.g., 20:1 THC:CBD flower): Best for severe pain and appetite stimulation. Strains such as Gelato or OG Kush are commonly prescribed.
• Balanced (1:1 THC:CBD oil): Effective for nausea with less psychoactive effect — often preferred during daytime use.
• CBD-dominant (e.g., 20:1 CBD:THC oil): Suits patients who cannot tolerate THC psychoactivity but need anti-inflammatory and anxiolytic support.

Explore available medical cannabis products and filter by THC:CBD ratio, or use the chronic pain condition guide for strain recommendations.

What to Expect at a Cancer-Focused Consultation

At a UK specialist consultation for cancer-related symptoms, expect to discuss your oncology history, current medications (including chemotherapy agents), pain scores, nausea frequency, sleep quality, and appetite. The clinician will assess drug interaction risks — particularly important given that CBD inhibits CYP3A4 and CYP2C9 enzymes that metabolise some chemotherapy drugs. Be transparent about your full medication list. Most initial consultations take 30 to 45 minutes and can be conducted online.

Side Effects and Safety Considerations for Cancer Patients

Cancer patients are often on complex medication regimens, making drug interaction assessment essential before starting medical cannabis. CBD inhibits CYP3A4 and CYP2C9 liver enzymes, which metabolise taxanes, vincristine, and several targeted therapies. Your specialist should review your full oncology medication list before prescribing.

Common side effects at therapeutic doses include dry mouth, mild dizziness, and short-term memory effects with high-THC products. For cancer patients already experiencing fatigue, the sedating properties of Indica-dominant products may be a benefit rather than a drawback. Most patients find that starting at a low dose (2.5mg THC equivalent) and titrating slowly over one to two weeks minimises adverse effects while allowing effective symptom management.